A 15-year-old tribal girl from Khammam district has undergone life-saving surgery after being diagnosed with a rare tumor ...

Linperlisib is under clinical development by Shanghai Yingli Pharmaceutical and currently in Phase I for Hematological Tumor.

The single-cell analysis revealed a diverse range of cell types within the tumor microenvironment (TME), including tumor cells, immune cells, and fibroblasts, with varying proportions across cases.

Early in 2024, we reported on the FDA's call for new boxed warnings on the labeling of all approved chimeric antigen receptor ...

KT-333 is under clinical development by Kymera Therapeutics and currently in Phase I for Unspecified B-Cell Lymphomas. According to GlobalData, Phase I drugs for Unspecified B-Cell Lymphomas does not ...

Clinical Features. Basal cell carcinoma (BCC) is the most common malignant eyelid tumor, accounting for 85% of all such tumors. [1] The tumor usually affects adults but may also occur in younger ...

18, 2024 — Scientists have generated human stem cell models which contain notochord ... lifetime could have implications ... How Breast Cancer Cells Survive in Bone Marrow After Remission ...

However, their effectiveness has plateaued due to therapeutic resistance that renders tumor-infiltrating lymphocytes ... Additionally, pharmacologic inhibition of T cell glycolysis under hypoxia ...

More than 66,000 Americans will be diagnosed with pancreatic cancer this year. Learn more about the disease and how PanCAN can help.

Other cancer immunotherapies include vaccines and T cell infusions. By tracking the fate of tumor-specific T cells mobilized in lymph nodes by dual blockade of PD-1 and TIGIT, we show that both ...

An FDA-approved medication called glucarpidase could serve as an antidote to kidney toxicity in patients receiving the ...

These new mutations may give rise to new characteristics of the cancer, such as the ability to spread more freely. Non-genetic cellular changes in cell behavior, called epigenetic changes, also occur.